1. Record Nr. UNINA9910140133003321 Autore Gad Shayne C. <1948->

Titolo Drug safety evaluation [[electronic resource] /] / Shayne Cox Gad

Hoboken, NJ,: Wiley, c2009 Pubbl/distr/stampa

ISBN 1-282-36841-9

> 9786612368417 0-470-46415-1 0-470-46409-7

Edizione [2nd ed.]

Descrizione fisica 1 online resource (1196 p.)

Pharmaceutical Development Series;; v.7 Collana

Disciplina 615.19

615/.19

Soggetti Drugs - Toxicology

Drugs - Testing

Lingua di pubblicazione Inglese

Formato Materiale a stampa

Livello bibliografico Monografia

Description based upon print version of record. Note generali

Includes bibliographical references and index. Nota di bibliografia

Nota di contenuto Drug Safety Evaluation: Contents: Preface: Acknowledgment: About the

Author; 1. Drug Development Process and Global Pharmaceutical Marketplace; 2. Regulation of Human Pharmaceutical Safety; 3. Prior Art and Its Use in Safety Assessment Process: 4. Screens in Safety and Hazard Assessment; 5. Formulations, Routes, and Dosage Design; 6. Single-Dose (Acute) and Pilot (DRF) Toxicity Testing in Drug Safety Evaluation; 7. Genotoxicity; 8. Repeat-Dose Toxicity Studies; 9. Immunotoxicology in Drug Development; 10. Nonrodent Animal Studies; 11. Developmental and Reproductive Toxicity Testing 12. Carcinogenicity Studies13. Histopathology in Nonclinical Pharmaceutical Safety Assessment; 14. Irritation and Local Tissue Tolerance in Pharmaceutical Safety Assessment; 15. Pharmacokinetics and Toxicokinetics in Drug Safety Evaluation; 16. Safety Pharmacology; 17. Special Concerns for Preclinical Evaluation of Biotechnology Products; 18. Safety Assessment of Inhalant and Dermal Route Drugs; 19. Special-Case Products: Imaging Agents and Oncology Drugs; 20. Occupational Toxicology in Pharmaceutical Industry

21. Strategy and Phasing for Nonclinical Drug Safety Evaluation in Discovery and Development of Pharmaceuticals 22. Application of In Vitro Techniques in Drug Safety Assessment; 23. Evaluation of Human Tolerance and Safety in Clinical Trials: FIM Trials and Beyond; 24. Postmarketing Safety Evaluation: Monitoring, Assessing, and Reporting of Adverse Drug Responses; 25. Statistics in Pharmaceutical Safety Assessment; 26. Combination Products: Drugs and Devices; 27. Qualification of Impurities, Degradants, Residual Solvents, and Leachables in Pharmaceuticals

Appendix A. Selected Regulatory and Toxicological AcronymsAppendix B. Definition of Terms and Lexicon of Clinical Observations in Nonclinical (Animal) Studies; Appendix C. Notable Regulatory Internet Addresses; Appendix D. Glossary of Terms Used in Clinical Evaluation of Therapeutic Agents; Appendix E. Common Vehicles for Nonclinical Evaluation of Therapeutic Agents; Appendix F. Global Directory of Contract Toxicology Laboratories; Index

Sommario/riassunto

Drug Safety Evaluation Second EditionShayne Cox Gad The updated and expanded safety guide to all aspects of the drug development process Drug Safety Evaluation, Second Edition presents an all-inclusive, practical guide for those who are responsible for ensuring the safety of drugs and biologics for patients, for health care providers, for those involved in the manufacture of medicinal products, and for all those who need to understand how the safety of these products is evaluated. This Second Edition has been extensively revised and expanded to respond to the many changes